CD3+ and CD8+ T cell-based immune cell score as a prognostic factor in clear-cell renal cell carcinoma

• Published in: Acta oncologica 2024-03, Vol.63 (1), p.105-110
• Main Authors: Åkerla, Jonne, Helminen, Olli, Väyrynen, Juha P, Parkkinen, Anne, Järvenpää, Hilma, Böhm, Jan, Ahtiainen, Maarit, Seikkula, Heikki
• Format: Article
• Language: English
• Subjects: Aged; Carcinoma; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - surgery; CD3; CD8; CD8-Positive T-Lymphocytes; Humans; immune cell score; immunohistochemistry; Kidney Neoplasms - pathology; Kidney Neoplasms - surgery; Lymphocytes, Tumor-Infiltrating - pathology; Prognosis; renal cell; Retrospective Studies; Short Report
• ISSN: 0284-186X; 1651-226X; 1651-226X
• DOI: 10.2340/1651-226X.2024.19690

Immunoscore® is a prognostic parameter based on densities of lymphocyte populations in the tumor center and invasive margin. Immunoscore® is validated in colorectal cancer as a high Immunoscore® is associated with longer survival. Previous studies have suggested that Immunoscore® may also predict oncological outcomes in clear-cell renal cell carcinoma (ccRCC). This study aims to assess the prognostic role of immune cell score in ccRCC. All patients with ccRCC undergoing surgery between 2007 and 2020 in Central Finland Central Hospital were retrospectively identified. CD3+ and CD8+ cell densities were calculated from tissue samples to determine the immune cell score using Immunoscore® principles. Receiver-operating characteristic analysis, Kaplan-Meier survival curve, and Cox regression were used to evaluate the association between immune cell score and survival. A total of 203 patients (mean age 66.5 years) were identified. The median follow-up time was 6.2 years. Based on the immune cell score, the patients were divided into three groups: low, intermediate, and high. In Cox regression analysis, adjusted with age, sex, and Charlson Comorbidity Index, no significant differences in disease-specific mortality were observed among the three groups. The hazard ratios (HRs) for disease-specific mortality were 0.93 (95% confidence interval [CI] 0.48-1.79) and 1.12 (0.52-2.37) for intermediate- and high-immune cell score groups when compared to low-immune cell score group, respectively. This study found no association between immune cell score and survival. These results indicate that immune cell score may not serve as a prognostic tool in ccRCC.